Certara Appoints Jon Resnick as Chief Executive Officer

Related news

CERTCertara2026-06-25 13:46 EST

Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2026

CERTCertara2026-06-25 13:46 EST

Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance

CERTCertara2026-06-25 13:46 EST

Certara to Participate in Upcoming Investor Conferences

CERTCertara2026-06-25 13:46 EST

Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib

CERTCertara2026-06-25 13:46 EST

Certara to Report First Quarter 2026 Financial Results on May 11th, 2026

CERTCertara2026-06-25 13:46 EST

Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat

View all latest news

Certara

Certara is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

CERTCertara2026-06-26 10:08 EST

Certara Announces CFO Transition

CERTCertara2026-06-26 10:08 EST

Certara Reports First Quarter 2026 Financial Results

CERTCertara2026-06-26 10:08 EST

Certara Automates Scientific Workflows with Phoenix® Cloud

CERTCertara2026-06-26 10:08 EST

Certara Reports Third Quarter 2025 Financial Results

CERTCertara2026-06-26 10:08 EST

Certara Appoints Jon Resnick as Chief Executive Officer

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States